Search

Author/Creator Cerva, C.

11. Quantitative HBeAg varies across the different phases of HBV infection, and can predict treatment outcome in the setting of HBV-reactivation driven by iatrogenic immunosuppression. (February 2020)

Authors:
Piermatteo, L.; Salpini, R.; Alkhatib, M.; Bertoli, A.; Iuvara, A.; De Cristofaro, M.; Cappiello, G.; Cerva, C.; Minichini, C.; Pisaturo, M.; Starace, M.; Coppola, N.; Fontana, C.; Sarmati, L.; Andreoni, M.; Angelico, M.; Grelli, S.; Silberstein, F. Ceccherini; Perno, C.F.; Svicher, V.
Journal:
Digestive and liver disease
Issue:
Volume 52(2020)Supplement 1
Page Start:
e21
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

12. Steatosis in patients with HCV chronic liver disease: Baseline results from patients enrolled in the PITER cohort study. (7th October 2015)

Authors:
Weimer, L.E.; Falzano, L.; Mallano, A.; Quaranta, M.G.; Massella, M.; Rosato, S.; Colombato, P.; Giubilei, L.; Ciancio, A.; Iannone, A.; Filomia, R.; Orlandini, A.; Petta, S.; Tamburrini, F.; Blanc, P.; D'Aversa, F.; Pasetto, M.C.; Erne, E.M.; Ieluzzi, D.; Storato, S.
Journal:
Digestive and liver disease
Issue:
Volume 47(2015)Supplement 3
Page Start:
e224
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

13. The combined usage of accurate virological and serological HBV markers can help to identify HBsAg-negative/anti-HBc-positive patients at higher risk of HBV-reactivation and to optimize prophylaxis duration in oncohematological setting. (February 2020)

Authors:
Salpini, R.; Alkhatib, M.; Cerva, C.; Piermatteo, L.; Battisti, A.; Malagnino, V.; Fabeni, L; Cantonetti, M.L.; Arcese, W.; Ceccherini-Silberstein, F.; Perno, C.F.; Andreoni, M.; Sarmati, L.; Svicher, V.
Journal:
Digestive and liver disease
Issue:
Volume 52(2020)Supplement 1
Page Start:
e23
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗